KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.

Abolghasem Allahyari, Ali Ehsanpour, Behrouz Najafi, Nafiseh Ansarinejad, Valiollah Mehrzad, Behjat Kalantari, Jahangir Raafat, Mojtaba Ghadiany, Farhad Shahi, Behrooz Gharib, Vahid Moazed, Adnan Khosravi, Mir Hossein Mirpour, Sina Salari, Seyedmohammadreza Mortazavizadeh, Amirabbas Nekoyi, Mohsen Khani, Alireza Sadeghi, Sirus Gharib, Alireza Bary, Mehrzad Mirzania, Shirin Haghighat, Seyed Mohsen Razavi, Seyed Amir Hossein Emami, Mehran Hosseinzadeh, Mahdi Mirbolouk, Sanambar Sadighi, Abdolali Shahrasbi, Ali Esfahani, Masoumeh Gity, Nassim Anjidani, Hamidreza Kafi, Safa Najafi

BMC Cancer 22(1) 960

PMID36071409
PMCIDPMC9450379
DOI10.1186/s12885-022-09895-5
发表日期2022-09-07
入排依据:While the record describes a Phase III randomized oncology trial with a drug intervention and reports original results, the primary efficacy endpoint is breast pathologic complete response (bpCR), which is a binary response endpoint, not a time-to-event outcome. No time-to-event endpoint (OS, PFS, DFS, EFS, RFS, TTP, or mention of Kaplan-Meier or HR) is specified as primary or key secondary.
摘要

摘要

BACKGROUND: Breast cancer is the most frequently diagnosed cancer and the leading reason for cancer-related death among women. Neoadjuvant treatment with dual-HER2 (human epidermal growth factor receptor 2) blockade has shown promising effects in this regard. The present study aimed to compare the efficacy and safety of a proposed pertuzumab biosimilar with the reference pertuzumab. METHODS: This randomized, phase III, multicenter, equivalency clinical trial was conducted on chemotherapy-naive women with HER2-positive breast cancer. Patients were randomly assigned (1:1) to receive six cycles of either P013 (CinnaGen, Iran) or the originator product (Perjeta, Roche, Switzerland) along with trastuzumab, carboplatin, and docetaxel every 3 weeks. Patients were stratified by cancer type (operable, locally advanced, inflammatory) and hormone receptor status. The primary endpoint was breast pathologic complete response (bpCR). Secondary endpoints included comparisons of total pCR, overall response rate (ORR), breast-conserving surgery (BCS), safety, and immunogenicity. RESULTS: Two hundred fourteen patients were randomized to treatment groups. bpCR rate in the per-protocol population was 67.62% in the P013 and 71.57% in the reference drug groups. Based on bpCR, P013 was equivalent to the reference pertuzumab with a mean difference of - 0.04 (95% CI: - 0.16, 0.09). Secondary endpoints were also comparable between the two groups. CONCLUSIONS: The proposed biosimilar P013 was equivalent to the reference product in terms of efficacy. The safety of both medications was also comparable.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。